Ercon Pharmaceutical Performance Report

Alcoa Pharmaceuticals recently released its third quarter report. The company is steadily developing.

From January to September 2012, the company achieved operating revenue of RMB 604,897,900, an increase of 31.84% over the same period of last year; net profit attributable to shareholders of listed companies was RMB 11,840.33 million, an increase of 35.77% over the same period of last year.

During the reporting period, the company actively explored the market, increased the market share of the company’s existing products, and ensured that the company’s product sales continued to grow steadily;

Grasp the timing of industry adjustment, strengthen production management, pay close attention to product quality, and maintain the company's leading position in the industry;

Intensify R&D efforts, increase R&D investment, and set up a subsidiary company Hunan Pharmaceutical Excipient Engineering Technology Research Center Co., Ltd. with its own funds to build a pharmaceutical R&D platform for pharmaceutical excipients to enhance R&D capabilities of the company's pharmaceutical excipients And core competitiveness;

Actively promote the construction of fund-raising projects, and at the same time adjust the implementation progress of fund-raising projects and new projects according to market changes;

At the same time, we continuously improved the corporate governance structure, and in accordance with relevant laws and regulations, we modified the company’s internal control system according to the company’s development needs.

During the reporting period, no major changes occurred in the company's main business and core technology team.